Speaking Engagements
Healthcare Securities Class Actions, SEC Enforcement & Emerging Capital Markets Risks
September 2, 2026
Douglas G. Gray, a partner in Troutman Pepper Locke’s Health Care + Life Sciences Department, was quoted in the July 29, 2026, Life Sciences IP Review article, “Where Big Pharma Is Betting Big in the M&A Boom.”
- Rayski says demand for GLP-1 and metabolic disease programmes is “particularly strong”, while Douglas Gray, partner at Troutman, describes the cardiometabolic and obesity space as “another highly competitive area”, with Big Pharma racing to stake a position in a market with “high commercial potential”.
- Rare diseases are also attracting growing attention. Gray says orphan drug exclusivity and premium pricing continue to make the area attractive, while Griebel says there is sustained interest in immunology and inflammation, neuroscience, rare diseases, and cell and gene therapies.
- Gray similarly points to AI-native biotech platforms as an emerging area for dealmaking.
Insight Industries + Practices
This just in
Speaking Engagements
PFAS for Decision Makers: Managing PFAS Risk in Today’s Deals – While Preparing for What’s Next
August 27, 2026 | 12:00 PM – 1:00 PM CT
Webinar
Firm Events
Cocktails and Networking During MEDevice Boston
August 26, 2026 | 6:00 PM – 8:00 PM ET
Lifted Restaurant
450 Summer St, Boston, MA 02210
Speaking Engagements
The 2026 Multifamily Maturity Cliff: Reading the $162 Billion Refinancing Wave and the Engagements It Will Generate
August 26, 2026 | 1:00 PM – 3:10 PM ET
Webinar